Abstract
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib, in combination with gemcitabine, has been shown to be a promising the......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
